Tumor vasculature as target for therapeutic intervention

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1321-1338

  Fens, Marcel H A M ^a   Storm, Gert ^a   Schiffelers, Raymond M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

angiogenesis; cancer; tumor vasculature; vascular active agents; vascular disrupting agents; vascular normalization

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; AG 0137; ANGINEX; ANGIOPOIETIN; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR; BAY 57 9352; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CYTOKINE; DENIBULIN; INTEGRIN; MONOCLONAL ANTIBODY IMC 1C11; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PLACENTAL GROWTH FACTOR; SEMAXANIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR; TW 152 F; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB; VOLOCIXIMAB;

ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77958478041     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.524204     Document Type: Review

References (185)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990. 61. 5. 759-67.
2. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358(5):502-11
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-60
5. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3-4):489-502
6. Qu B, Guo L, Ma J, Lv Y. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses 2010;74(2):360-1
7. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-65
8. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15(1):102-11
9. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5(6):436-46
10. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991;51(1):265-73
11. Tozer GM, Ameer-Beg SM, Baker J, et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 2005;57(1):135-52
12. Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000;60(14):3683-8
13. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156(4):1363-80
14. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000;19(1-2):109-20
15. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95(8):4607-12
16. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2(4):266-76
17. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2(2):83-90
18. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438(7070):932-6
19. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
20. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348(6301):555-7
21. Seaman S, Stevens J, Yang MY, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11(6):539-54
22. Mueller MM, Fusenig NE. Friends or foes? Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4(11):839-49
23. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76(1):69-125
24. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3(6):422-33
25. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160(3):985-1000
26. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6(5):392-401
27. Haviv I, Polyak K, Qiu W, et al. Origin of carcinoma associated fibroblasts. Cell Cycle 2009;8(4):589-95
28. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-44
29. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008;659(1-2):15-30
30. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124(2):263-6
31. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66(2):605-12
32. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
33. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685-93
34. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
36. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
37. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
38. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs 1997;79:233-69
39. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60(16):4556-60
40. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57(5):963-9
41. Eliceiri BP, Cheresh DA. The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103(9):1227-30
42. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50(2):197-263
43. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89(6):2018-22
44. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology (Williston Park) 2007;21(9 Suppl 3):13-20
45. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264(5158):569-71
46. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic Nat Med 2003;9(6):713-25
47. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96(4):1815-22
48. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79(7):1157-64
49. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha vintegrins. Cell 1998;95(4):507-19
50. Nyberg P, Xie L, Kalluri R Endogenous inhibitors of angiogenesis. Cancer Res 2005;65(10):3967-79
51. Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 2004;112(7-8):450-62
52. Ribatti D. Endogenous inhibitors of angiogenesis A historical review. Leuk Res 2009;33(5):638-44
53. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9(3):267-82
54. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45(1):136-9
55. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74
56. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001;7(Suppl 3):S120-8
57. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
58. Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by I.C.R. F. 159: selective deletion of a malignant characteristic Br Med J 1970;4(5731):344-6
59. Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159:a new type of drug action. Br Med J 1972;1(5800):597-601
60. Hellmann K. Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clin Exp Metastasis 2003;20(2):95-102
61. Rybak SM, Sanovich E, Hollingshead MG, et al. 'Vasocrine' formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003;63(11):2812-19
62. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
63. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979-86
64. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565-70
65. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13(6):223-30
66. Sartore-Bianchi A, Ricotta R, Cerea G, et al. Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers 2007;22(1 Suppl 4):S77-87
67. Willett CG, Duda DG, di Tomaso E, et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007;4(5):316-21
68. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148(4):616-32
69. Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14(2):157-63
70. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52
71. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988;48(8):2179-83
72. Ten Hagen TL, Van Der Veen AH, Nooijen PT, et al. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000;87(6):829-37
73. Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
74. Kim DW, Andres ML, Li J, et al. Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res 2001;21(11):885-97
75. Hoving S, Seynhaeve AL, van Tiel ST, et al. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anticancer Drugs 2006;17(8):949-59
76. Brunstein F, Hoving S, Seynhaeve AL, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004;96(21):1603-10
77. Hoving S, Brunstein F, aan de Wiel-Ambagtsheer G, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005;65(10):4300-8
78. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007;14(1):230-8
79. Grunhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006;3(2):94-103
80. Verhoef C, de Wilt JH, Grunhagen DJ, et al. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol 2007;8(6):417-27
81. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5(6):423-35
82. Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984;312(5991):237-42
83. Bayless KJ, Davis GE. Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. J Biol Chem 2004;279(12):11686-95
84. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99(6):2060-9
85. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 2007;11(11):1443-57
86. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8(6):1974-83
87. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-27
88. Thorpe PE, Chaplin DJ, Blakey DC The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63(5):1144-7
89. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53(1):164-71
90. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54(5):1512-17
91. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99(1):1-6
92. Martinelli M, Bonezzi K, Riccardi E, et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007;97(7):888-94
93. Masunaga S, Sakurai Y, Suzuki M, et al. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy. Int J Radiat Oncol Biol Phys 2004;60(3):920-7
94. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57(4):1047-55
95. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62(3):846-53
96. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6(8):465-77
97. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24(10):1491-8
98. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207(3):491-503
99. Luckner SR, Klotzsche M, Berens C, et al. How an agonist peptide mimics the antibiotic tetracycline to induce Tet-repressor. J Mol Biol 2007;368(3):780-90
100. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20(18):3792-803
101. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21(2):223-31
102. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(22):3555-61
103. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301(5):1179-90
104. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275(28):21340-8
105. Lawler J, Detmar M. Tumor progression: the effects ofthrombospondin-1 and-2. Int J Biochem Cell Biol 2004;36(6):1038-45
106. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23(22):5188-97
107. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26(34):5583-8
108. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60(9):2520-6
109. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275(2):1209-15
110. Mongiat M, Sweeney SM, San Antonio JD, et al. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003;278(6):4238-49
111. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986;46:1-265
112. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285(5425):245-8
113. Kurup A, Lin CW, Murry DJ, et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17(1):97-103
114. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285(5435):1926-8
115. Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998;273(44):28805-12
116. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247(4938):77-9
117. Hayami T, Shukunami C, Mitsui K, et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 1999;458(3):436-40
118. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295(5564):2387-92
119. James J, Murry DJ, Treston AM, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25(1):41-8
120. Rajkumar SV, Richardson PG, Lacy MQ, et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007;13(20):6162-7
121. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188(12):2349-56
122. Mita MM, Rowinsky EK, Forero L, et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 2007;59(2):165-74
123. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64(14):4931-41
124. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102(8):2763-7
125. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001;354(Pt 2):233-42
126. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26(6):919-24
127. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
128. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004;26(7):587-612
129. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94(11):1621-6
130. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 2009;8(1):59-60
131. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26(33):5407-15
132. Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14(1):22-8
133. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227-34
134. Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006;33(5 Suppl 10):S35-40
135. Jayson GC, Mulatero C, Ranson M, et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 2005;41(4):555-63
136. Posey JA, Ng TC, Yang B, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9(4):1323-32
137. Lau SC, Rosa DD, Jayson G. Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr Opin Mol Ther 2005;7(5):493-501
138. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
139. McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a monoclonal antibody specific for alpha-v-beta-3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11(21):7851-60
140. Delbaldo C, Raymond E, Vera K, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alpha-v-beta-3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008;26(1):35-43
141. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alpha-v integrins. Int J Cancer 2000;87(5):716-23
142. Ricart AD, Tolcher AW, Liu G, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alph-5-beta-1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14(23):7924-9
143. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444(7122):1083-7
144. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
145. Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 2008;98(3):148-55
146. Rossi CR, Russano F, Mocellin S, et al. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial. Ann Surg Oncol 2008;15(4):1218-23
147. Joensuu H, De Braud F, Coco P, et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008;19(1):173-7
148. Brunstein F, Rens J, van Tiel ST, et al. Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer 2006;95(12):1663-9
149. Brunstein F, Eggermont AM, de Wiel-Ambagtsheer G, et al. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases. Ann Surg Oncol 2007;14(2):795-801
150. Blakey DC, Ashton SE, Westwood FR, et al. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54(5):1497-502
151. LoRusso PM, Gadgeel SM, WozniakA, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26(2):159-67
152. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21(15):2815-22
153. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 2006;7(6):522-8
154. Hori K, Saito S, Sato Y, et al. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 2003;39(13):1957-66
155. Kirwan IG, Loadman PM, Swaine DJ, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004;10(4): 1446-53
156. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99(12):2006-12
157. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Investig Drugs 2008;17(10):1547-51
158. Cai SX. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007;2(1):79-101
159. Fox E, Maris JM, Widemann BC, et al. A phase 1 study ofABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12(16):4882-7
160. Mauer AM, Cohen EE, Ma PC, et al. A phase II study ofABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3(6):631-6
161. Yamamoto N, Andoh M, Kawahara M, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci 2009;100(2):316-21
162. Patel S, Keohan ML, Saif MW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006;107(12):2881-7
163. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92(3):391-400
164. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173(2):219-38
165. Moses MA, Wiederschain D, Wu I, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 1999;96(6):2645-50
166. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
167. Strumberg D, Schultheis B, Adamietz IA, et al. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer 2008;99(10):1579-85
168. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
169. Seynhaeve AL, de Wilt JH, van Tiel ST, et al. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer 2002;86(7):1174-9
170. Ten Hagen TL, Hoving S, Ambagtsheer G, et al. Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats. Br J Cancer 2004;90(9):1830-2
171. van Ijken MG, van Etten B, de Wilt JH, et al. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 2000;23(4):449-55
172. Tomazic VJ, Farha M, Loftus A, Elias EG. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J Immunol 1988;140(11):4056-61
173. Brouckaert P, Takahashi N, van Tiel ST, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004;109(3):442-8
174. Hoving S, Seynhaeve AL, van Tiel ST, et al. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Anticancer Drugs 2005;16(6):667-74
175. KrosnickJA, Mule JJ, McIntoshJK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989;49(14):3729-33
176. Suzuki S, Ohta S, Takashio K, et al. Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J Cancer 1990;46(6):1095-100
177. Hoving S, van Tiel ST, Eggermont AM, ten Hagen TL. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue-and osteosarcoma-bearing rats. Anticancer Res 2005;25(2A):743-50
178. Ten Hagen TL, Seynhaeve AL, van Tiel ST, et al. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 2002;97(1):115-20
179. Saito M, Fan D, Lachman LB. Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice. Clin Exp Metastasis 1995;13(4):249-59
180. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18(11):1185-90
181. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110(4):475-82
182. Crippa L, Gasparri A, Sacchi A, et al. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res 2008;68(4):1154-61
183. Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alpha-V integrin ligands improves its antineoplastic activity. Cancer Res 2004;64(2):565-71
184. Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17(1):25-31
185. Kasibhatla S, Baichwal V, Cai SX, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007;67(12):5865-71